Drug spending tops $1 trillion on hepatitis C, cancer therapies: Study

Hepatitis C drugs will add about $100 billion in total spending in the next few years, while cancer spending will rise to $100 billion.
Source: The Economic Times - Category: Consumer Health News Source Type: news

Related Links:

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
This study examined the impact of HCV on neurocognitive function and health‐related quality of life (HRQOL) among adult survivors of childhood cancer. METHODSNeurocognitive testing was conducted for 836 adult survivors of childhood cancer (mean age, 35 years [standard deviation, 7.4 years]; time since diagnosis, 29 years [standard deviation, 6.2 years]) who received blood products before universal HCV screening. No differences were observed between confirmed HCV‐seropositive survivors (n = 79) and HCV‐seronegative survivors (n = 757) in the primary diagnosis or neurotoxic therapies. Multivariate regression models wer...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Filtering infectious pathogens and cancer cells directly from whole blood has been an almost fantastic proposition, but the Hemopurifier from Aethlon Medical does just that. We’ve been covering it for over 10 years on Medgadget as it ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Oncology Source Type: blogs
Abstract Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about the management of HCV infection in patients with cancer. The substantial burden of HCV infection and the inconclusive evidence regarding its detection and management in patients with cancer prompted the authors to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematologic malignancies, hemat...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: CA Cancer J Clin Source Type: research
Abstract Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in retrospective studies. We sought to determine prospectively the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment. HCV‐infected patients receiving cancer treatment at our institution (11/2012‐07/2016) were studied. Reactivation was defined as an increase in HCV‐RNA ≥1 log10 IU/mL over baseline and hepatitis flare as alanine aminotransferase (ALT) increase to ≥3 times the upper limit of normal. One hundred patients were studied, 50 with hematologic malignancies and ...
Source: Hepatology - Category: Internal Medicine Authors: Tags: Viral Hepatitis Source Type: research
This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.
Source: Blood - Category: Hematology Authors: Tags: Transplantation, How I Treat, Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Abstract Claudin-1 (CLDN-1), an integral transmembrane protein, is an attractive target for drug absorption, prevention of infection, and cancer therapy. Previously, we generated mouse anti-CLDN-1 monoclonal antibodies (mAbs) and found that they enhanced epidermal absorption of a drug and prevented hepatitis C virus infection in human hepatocytes. Here, we investigated anti-tumor activity of a human-mouse chimeric IgG1, xi-3A2, from one of the anti-CLDN-1 mAbs, clone 3A2. Xi-3A2 accumulated in the tumor tissues in mice bearing with human CLDN-1-expressing tumor cells. Xi-3A2 activated Fcγ receptor IIIa-expre...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
This report concluded there was value in these therapies but also raised concerns about whether their effects will translate into lower rates of heart attack and stroke. Further, ICER concluded that a discount of 67 percent off the drugs’ list price would better represent their overall benefit. ICER’s assessment is still in draft form and it remains unclear whether the report will have any effect. Nevertheless, such work is a step in the right direction. Other entities are developing alternative methods to evaluate prescription drugs. The American Society for Clinical Oncology has sought comment on its proposed...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: Costs and Spending Drugs and Medical Technology Featured Payment Policy Quality Big Pharma Biosimiliar Comparative Effectiveness FDA PCSK9 inhibitors Sovaldi specialty drugs Source Type: blogs
Conclusion Fibroscan correlated with histopathology in moderate (F2–F3), but not mild (F1) fibrosis. The degree of fibrosis regresses significantly in HCV responders on anti-viral INF based therapy. Besides its accuracy as noninvasive device in detecting degree of fibrosis, fibroscan can be very useful in assessment of degree of fibrosis during and after therapy.
Source: The Egyptian Journal of Radiology and Nuclear Medicine - Category: Nuclear Medicine Source Type: research
By SUSAN DENTZER Global New Active Substances (NAS) Available Since 1996 Here’s the problem with high and rising pharmaceutical prices:  It’s not just one problem, but many.  Addressing them will require a range of solutions – many of them difficult to execute, and possibly tough medicine to swallow. These were key takeaways from the recent U.S. Department of Health and Human Services Pharmaceutical Forum,which I moderated.  A broad group of stakeholders participated, including patients, consumer groups, pharmaceutical companies, pharmacy benefits managers, insurers and others.  The ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: THCB Susan Dentzer Source Type: blogs
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hepatitis | Hepatitis C | Study